How to Counsel Your Vaccine-Hesitant Patients

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How to Counsel Your Vaccine-Hesitant Patients



ReachMD Healthcare Image

How should we talk to our patients who are hesitant about shingles vaccination?

Sponsored by GSK

  • Sponsored by

  • Overview

    Joining Dr. Jennifer Caudle to discuss how to talk to vaccine-hesitant patients about shingles vaccination and share insights is Dr. Christopher Altman, Director of Immunization and Clinical programs.

    Sponsored by GSK


    SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

    SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).


    • SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
    • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
    • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
    • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
    • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
    • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
    • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
    • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
    • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

    Please see full Prescribing Information for SHINGRIX.

    Trademarks are property of their respective owners.

    ©2022 GSK or licensor.
    SGXWCNT220053 December 2022
    Produced in USA.

Schedule3 Jun 2023